KR950703580A - CETP 억제 폴리펩티드, 그 합성 폴리펩티드에 대한 항체 및 아테롬성 동맥경화증의 예방학적 및 치료학적 처치(CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments) - Google Patents
CETP 억제 폴리펩티드, 그 합성 폴리펩티드에 대한 항체 및 아테롬성 동맥경화증의 예방학적 및 치료학적 처치(CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments) Download PDFInfo
- Publication number
- KR950703580A KR950703580A KR1019950701273A KR19950701273A KR950703580A KR 950703580 A KR950703580 A KR 950703580A KR 1019950701273 A KR1019950701273 A KR 1019950701273A KR 19950701273 A KR19950701273 A KR 19950701273A KR 950703580 A KR950703580 A KR 950703580A
- Authority
- KR
- South Korea
- Prior art keywords
- lys
- glu
- leu
- ser
- ala
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10216093A | 1993-08-04 | 1993-08-04 | |
US08/102160 | 1993-08-04 | ||
PCT/US1994/008624 WO1995004755A1 (en) | 1993-08-04 | 1994-08-02 | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950703580A true KR950703580A (ko) | 1995-09-20 |
Family
ID=22288420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950701273A KR950703580A (ko) | 1993-08-04 | 1994-08-02 | CETP 억제 폴리펩티드, 그 합성 폴리펩티드에 대한 항체 및 아테롬성 동맥경화증의 예방학적 및 치료학적 처치(CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments) |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0664813A4 (ja) |
JP (1) | JPH08502525A (ja) |
KR (1) | KR950703580A (ja) |
AU (1) | AU683295B2 (ja) |
CA (1) | CA2145767A1 (ja) |
WO (1) | WO1995004755A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039168A1 (en) | 1995-06-06 | 1996-12-12 | The Immune Response Corporation | Method for increasing hdl cholesterol level |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4904481A (en) * | 1985-04-17 | 1990-02-27 | The Board Of Trustess Of Leland Stanford University | Method of conferring immuno-tolerance to a specific antigen |
EP0618803A4 (en) * | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS. |
-
1994
- 1994-08-02 KR KR1019950701273A patent/KR950703580A/ko not_active Application Discontinuation
- 1994-08-02 EP EP94925711A patent/EP0664813A4/en not_active Withdrawn
- 1994-08-02 WO PCT/US1994/008624 patent/WO1995004755A1/en not_active Application Discontinuation
- 1994-08-02 AU AU75526/94A patent/AU683295B2/en not_active Expired
- 1994-08-02 CA CA002145767A patent/CA2145767A1/en not_active Abandoned
- 1994-08-02 JP JP7506464A patent/JPH08502525A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU683295B2 (en) | 1997-11-06 |
JPH08502525A (ja) | 1996-03-19 |
WO1995004755A1 (en) | 1995-02-16 |
CA2145767A1 (en) | 1995-02-16 |
AU7552694A (en) | 1995-02-28 |
EP0664813A4 (en) | 1998-05-27 |
EP0664813A1 (en) | 1995-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0477295B2 (en) | Platelet aggregation inhibitors | |
US5935926A (en) | Platelet aggregation inhibitors | |
Wilkinson | Troponin C from rabbit slow skeletal and cardiac muscle is the product of a single gene | |
US7094760B2 (en) | Peptides for treatment of inflammation and shock | |
EP2327712A3 (en) | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides | |
CA2155303A1 (en) | Treatment for insulin dependent diabetes | |
ATE413189T1 (de) | Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1 | |
KR950701818A (ko) | 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues) | |
Calderón et al. | Immunochemical Characterization and Role in Toxic Activities of Region 115–129 of Myotoxin II, a Lys49 Phospholipase A2fromBothrops asperSnake Venom | |
EP0557442A1 (en) | Antithrombosis agents | |
RU97105374A (ru) | Модифицированные белки | |
CA2053799C (en) | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid | |
US3864481A (en) | Anti disease producing synthetic material for the prevention suppression and diagnosis of multiple sclerosis and method of treatment therefor | |
Timpl et al. | Characterization of conformation independent antigenic determinants in the triple-helical part of calf and rat collagen | |
Bidart et al. | Antigenic determinants on human choriogonadotropin alpha-subunit. I. Characterization of topographic sites recognized by monoclonal antibodies. | |
AU679913B2 (en) | Stable polypeptide composition | |
US5344783A (en) | Platelet aggregation inhibitors | |
KR950703580A (ko) | CETP 억제 폴리펩티드, 그 합성 폴리펩티드에 대한 항체 및 아테롬성 동맥경화증의 예방학적 및 치료학적 처치(CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments) | |
Dixit et al. | Type IV collagens: isolation and characterization of 7S collagen from human kidney, liver and lung | |
Gregerson et al. | Preparation, isolation, and immunochemical studies of the cyanogen bromide peptides from a retinal photoreceptor cell autoantigen, S-antigen. | |
NZ324100A (en) | Luminal cholecystokinin-releasing factor | |
WO1997015671A9 (en) | Luminal cholecystokinin-releasing factor | |
Benson et al. | Amino terminal sequence of amyloid P-component isolated from serum | |
Swanborg | Antigen-induced inhibition of experimental allergic encephalomyelitis. IV. Studies of the C-terminal end of the myelin basic protein molecule (1) | |
KR910007963A (ko) | pST의 일부분에 대응하는 아미노산 서열을 갖는 펩티드, 그에 대한 항체 및 pST 활성에 효력을 더하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |